Antiproliferative Mechanisms of Metformin in Breast Cancer: A Systematic Review of the Literature
Moldasheva A. Zhakupova A. Aljofan M.
January 2025Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences
2025#26Issue 1
Metformin is an antidiabetic drug with reported potential antiproliferative activity against different cancer types including breast cancer. However, the mechanism of action of how metformin can induce its antiproliferative activity is still unclear. Thus, the current study is a systematic review of the literature aiming to explore the reported antiproliferative mechanisms of metformin against breast cancer. The study included seventeen research articles that describe different mechanisms of action against breast cancer. While the majority of the studies confirm the antiproliferative potential of metformin, albeit at different potencies, there appear to be various mechanisms and factors that can influence this effect. There are a number of questions yet to be answered pertaining the use of metformin as an anti-cancer agent, warranting further investigation into this emerging area of research.
AMPK , breast cancer , metformin , mTOR , systematic review
Text of the article Перейти на текст статьи
Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Laboratory of Drug Discovery and Development, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, 010000, Kazakhstan
Department of Biomedical Sciences
Laboratory of Drug Discovery and Development
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026